Splitomicin, >=98% (HPLC), powder

Splitomicin, >=98% (HPLC), powder

Stock Code: 3573904
Manufacturer Part No: S4068-5MG
Order Now for 21 day delivery
£107.25 (exc VAT) per 5MG
Quantity: - +

Application


Splitomicin was used to inhibit SIRT1 in human aortic endothelial cells and sirtuins in human breast cancer cells. Mouse leukaemic monocyte macrophage cell line was treated with Splitomicin prior to cholesterol efflux studies.


Biochem/physiol Actions


Sir2p (silent information regulator) and HDAC inhibitor.


Splitomicin, a derivative of ?-naphthol is an inhibitor of Silent Information Regulator 2 (SIR2). It inhibits the NAD+-dependent deacetylase activity of Sir2 in vitro. It increases the levels of cyclic AMP by inhibiting the activity of cyclic AMP phosphodiesterase, interferes with mobilization of intracellular Ca+2 and ATP release. This results in inhibition of platelet aggregation that is effective in cardiovascular and cerebrovascular diseases.


Features and Benefits


This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.


Packaging


5 mg in glass bottle

Quality Level100
InChI keyISFPDBUKMJDAJH-UHFFFAOYSA-N
InChI1S/C13H10O2/c14-13-8-6-11-10-4-2-1-3-9(10)5-7-12(11)15-13/h1-5,7H,6,8H2
ManufacturerSIGMA-ALDRICH
Storage Temp.2-8°C
Formpowder
Assay≥98% (HPLC)

There are no downloads for this product.